AAM Statement on Senate Finance Hearing on FDA’s Foreign Manufacturing Inspection Process

WASHINGTON, DC (June 2, 2020) — The COVID-19 crisis exposed many shortcomings in our health care system’s ability to respond to a pandemic. At the same time, many parts of that same system — including the supply chain for the vast majority of generic medicines — demonstrated extraordinary resiliency in the face of unprecedented stresses.

AAM Member Fresenius Kabi Testifies Before Congress on Drug Compounding

On January 30, Fresenius Kabi USA Vice President of Regulatory Affairs Molly Ventrelli testified before Congress on compounding.

The House Energy & Commerce Committee held a hearing on “Examining Implementation of the Compounding Quality Act.” Fresenius Kabi is a global health care company specializing in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

The company operates 18 compounding centers around the world, and is in the process of launching its first U.S.-based, 503B compounding center in suburban Boston.

Subscribe to Quality

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.